Floatz logo

ip-001

Soft Tissue Sarcoma

Immunophotonics, Inc.Phase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

44 Active assets in the Soft Tissue Sarcoma cohort.

Asset / SponsorPhaseRating
Inno-206
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3BB
Cyclophosphamide
Medigene AG
Phase 2BB
Tislelizumab
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3BB
Durvalumab
Institut Bergonié
Phase 2B
ETOPOSIDE
Masonic Cancer Center, University of Minnesota
Phase 2B

View all 50 →

Same molecule, other indications

ip-001 is also rated in:

metastasis from malignant tumor of colonDormant
BB
Indicative ·
64 / 100
View asset →
Colon Cancer Liver MetastasesDormant
B
Indicative ·
57 / 100
View asset →
rectal cancerDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →